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Abstract
Background We recently reported that miR-1 was one of
the most significantly downregulated microRNAs in gastric
cancer (GC) patients from The Cancer Genome Atlas
microRNA sequencing data. Here we aim to elucidate the
role of miR-1 in gastric carcinogenesis.
Methods We measured miR-1 expression in human GC
cell lines and 90 paired primary GC samples, and analyzed
the association of its status with clinicopathological fea-
tures. The effect of miR-1 on GC cells was evaluated by
proliferation and migration assay. To identify the target
genes of miR-1, bioinformatic analysis and protein array
analysis were performed. Moreover, the regulation mech-
anism of miR-1 with regard to these predicted targets was
investigated by quantitative PCR (qPCR), Western blot,
ELISA, and endothelial cell tube formation. The putative
binding site of miR-1 on target genes was assessed by a
reporter assay.
Results Expression of miR-1 was obviously decreased in
GC cell lines and primary tissues. Patients with low miR-1
expression had significantly shorter overall survival com-
pared with those with high miR-1 expression
(P = 0.0027). Overexpression of miR-1 in GC cells
inhibited proliferation, migration, and tube formation of
endothelial cells by suppressing expression of vascular
endothelial growth factor A (VEGF-A) and endothelin 1
(EDN1). Conversely, inhibition of miR-1 with use of
antago-miR-1 caused an increase in expression of VEGF-A
and EDN1 in nonmalignant GC cells or low-malignancy
GC cells.
Conclusions MiR-1 acts as a tumor suppressor by
inhibiting angiogenesis-related growth factors in human
gastric cancer. Downregulated miR-1 not only promotes
cellular proliferation and migration of GC cells, but may
activates proangiogenesis signaling and stimulates the
proliferation and migration of endothelial cells, indicating
the possibility of new strategies for GC therapy.
Keywords miR-1  Gastric cancer  Vascular endothelial
growth factor A  Angiogenesis
Introduction
Gastric cancer (GC) is the third commonest cause of cancer
deaths worldwide [1]. In 2012, 42.54% of global new GC
cases and 44.95% of global GC deaths occurred in China
[1, 2]. Metastasis is the overwhelming cause of treatment
failure in patients with GC. Therefore, a better under-
standing of the molecular mechanisms underlying distant
metastasis would facilitate the development of novel
effective therapeutic strategies for GC patients.
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MicroRNAs (miRNAs) are endogenous, small noncod-
ing RNAs that have an ability to promote or suppress the
expression of many genes. They are involved in cell sig-
naling pathways essential for tumor occurrence and pro-
gression, such as cell proliferation, mobility, apoptosis, and
angiogenesis [3, 4].
Accumulating evidence has revealed aberrant expres-
sion of specific miRNAs in various malignant tumors,
including GC. Our previous study analyzing miRNA
sequencing data of GC from The Cancer Genome Atlas
(TCGA) website revealed that miR-1 was markedly
downregulated in GC compared with adjacent nonmalig-
nant tissue samples. It ranked as the most decreased
miRNA in the chromosome instability subgroup of GC,
which accounted for half of the total tumors tested [5].
MiR-1, sharing a similar seed sequence with miR-206, was
originally described as muscle specific, and has been
shown to downregulate MET, FOXP1, KRAS, PIK3CA, and
NAIP, which are important oncogenes relating to tumori-
genic properties of various cancer types [6–10] and even
tumor-associated macrophages [11]. Microarray analysis
on biopsy samples from 90 GC patients and 34 healthy
volunteers by Kim et al. [12] revealed that miR-1 was one
of the mostly downregulated miRNAs in GC. Conversely,
Liu et al. [13] found that serum miR-1 concentration was
significantly high in GC patients compared with control
individuals. Patients with high expression of serum miR-1
showed resistance to fluoropyrimidine-based chemotherapy
[14]. Furthermore, no study has investigated the clinical
significance of miR-1 expression in GC tissue samples.
Angiogenesis has a major function in tumor develop-
ment and progression. In this setting, clinical data suggest
that targeting angiogenesis by inhibiting angiogenic sig-
naling pathways is an important therapeutic activity for
many solid tumors, including GC. However, evidence of
antitumor activity with antiangiogenic therapies leading to
improved overall survival or progression-free survival in
patients with metastatic GC is still limited [15, 16].
Vascular endothelial growth factor (VEGF)-A is a key
regulator of angiogenesis [17]. In patients with GC, cir-
culating VEGF-A levels are associated with increased
tumor aggressiveness and reduced survival [18, 19]. The
mechanisms that modulate the level of VEGF-A expressed
by the producing cells are gradually being uncovered.
Stahlhut et al. [20] demonstrated that miR-1 negatively
regulated angiogenesis by suppressing VEGFA during
zebrafish development. VEGFA and miR-1 are well con-
served across all species, indicating that the same phe-
nomenon may possibly occur during carcinogenesis.
Accordingly, in this study we characterized miR-1
expression in GC cell lines and primary GC tissues, and
investigated its functional role in GC pathogenesis. We
quantified miR-1 expression in both tumor and
corresponding nontumor tissues, and analyzed the rela-
tionships between the levels of miR-1 expression and
clinicopathological parameters in 90 Chinese patients with
GC. We found that miR-1 was frequently downregulated in
tumor tissues compared with corresponding nontumor tis-
sues, and that low expression of miR-1 was correlated with
poor prognosis. The effects of miR-1 on gastric carcino-
genesis were evaluated by gain-of-function experiments.
Overexpression of miR-1 significantly weakened malignant
behavior of GC cells and tube formation of endothelial
cells by directly suppressing VEGFA and EDN1
expression.
Materials and methods
GC samples
Ninety matched GC and adjacent nontumor mucosal tis-
sues (more than 5 cm laterally from the edge of the
cancerous region) were collected from patients undergoing
radical surgical resection at Peking University Beijing
Cancer Hospital from January 2004 to December 2010.
After gastrostomy, resected specimens were processed
routinely for macroscopic pathological assessment, then
harvested and frozen in -80 C freezer. GC stage was
classified according to the 2010 TNM classification rec-
ommended by the American Joint Committee on Cancer.
Patient records were reviewed in the context of clinico-
pathology and follow-up information. All patients were
tracked until March 2015. None of the patients received
preoperative chemotherapy or radiation therapy before
surgery. All samples were obtained with the patient’s
informed consent. The Ethics Committee of Beijing Cancer
Hospital approved this study.
Cancer cell culture
One immortalized gastric mucosal epithelial cell line
(GES-1) and 6 GC cell lines (SGC7901, MKN28, NCI-
N87, BGC823, AGS, and HGC27) were cultured for miR-1
expression evaluation. The SGC7901 and BGC823 cell
lines were acquired from the Cell Research Institute
(Shanghai, China). The NCI-N87, AGS, and COS-7 cell
lines were purchased from ATCC (Manassas, VA, USA),
The HGC27 and MKN28 cell lines were obtained from the
European Collection of Authenticated Cell Cultures (Por-
ton Down, UK) and the Health Science Research Resour-
ces Bank (Tokyo, Japan) respectively. COS-7 cells were
used for miR—mRNA interaction reporter assays only.
Cell lines were cultured in Dulbecco’s modified Eagle’s
medium (HyClone, Logan, UT, USA) supplemented with
10% (v/v) fetal bovine serum (Gibco-BRL, Invitrogen,
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Paisley, UK) and penicillin at 100 U/mL and streptomycin
at 100 U/mL at 37 C in a 5% CO2 incubator.
5-Aza-20-deoxycyridine treatment
After being seeded at a density of 106 cells per 10-cm dish
on day 0, the GC cell lines were treated with freshly pre-
pared 1 lM 5-aza-20-deoxycyridine (5-aza-dC; Sigma, UK)
for 24 h on days 1, 3, and 5. After each treatment, the
medium was replaced with normal medium and harvested
on day 6 for RNA extraction.
Transient transfection
Logarithmically growing BGC823, SGC7901, AGS and
HGC27 cells were seeded in a 10-cm dish (6 9 106 cells
per flask), and then transfected with 16 lg GV268-miR-1
(hsa-miR-1-1) or a nonspecific GV268-ctrl plasmid (Gen-
eChem, China) for miR-1 overexpression and 30 nM
antago-miR-1 or antago-miR negative control for miR-1
suppression (Ambion, Austin, TX, USA) with Lipofec-
tamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). The
culture medium was replaced after 6 h, and then protein or
RNA was extracted from subconfluent cells after trans-
fection for 48 h.
RNA extraction, reverse transcription,
and quantitative real-time PCR
Total RNA was extracted from tissues or cultured cells
with Trizol reagent. For messenger RNA (mRNA)
expression analysis, RNA was reverse transcribed with
Moloney murine leukemia virus reverse transcriptase (In-
vitrogen) with oligo(dT)15 primers. The complementary
DNA was amplified with specific primers and Power
SYBR Green PCR master mix (Applied Biosystems, Foster
City, CA, USA). The glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) mRNA level was used as an internal
normalization control. The sequences of the primers used
were as follows: VEGF-A 50-CCTGGTGGACATCTTCC
AGGAGTACC-30 (forward), 50-GAAGCTCATCTCTCC
TATGTGCTGGC-30 (reverse); EDN1 50-AGCCTCCTCT
GCTCTTTCTGCTGGA-30 (forward), 50-CTTTTGTCTAT
GCCCCTGCAGCCTT-30 (reverse); MET 50-CTTTGTG
AGCAGATGCGGAG-30 (forward), 50-GGTTTATCTTTC
GGTGCCCAG-30 (reverse); GAPDH 50-ATGGGGAAGG
TGAAGGTCG-30 (forward), 50-GGGGTCATTGATGGC
AACAATA-30 (reverse). TaqMan microRNA assays (Ap-
plied Biosystems) were used to quantify miR-1 (assay ID
002222) expression, and SNORD48 (assay ID 001006) was
used as the endogenous control. Gene-specific reverse
transcription for miR-1 and SNORD48 was carried out
using about 500 ng of purified total RNA, 0.15 lL of
100 mM dNTPs (with dTTP), 1.5 lL MultiScribe reverse
transcriptase (50 U/lL), 1.5 lL 109 reverse transcription
buffer, 0.188 lL RNase inhibitor, 3.0 lL 59 TaqMan
miRNA reverse transcription primer, and 4.162 lL nucle-
ase-free water. A 15-lL reaction mixture was incubated for
30 min at 16 C, 30 min at 42 C, and 5 min at 85 C to
inactivate the reverse transcriptase. Then 1.33 lL reverse
transcription product, 7.67 lL nuclease-free water, 10 lL
TaqMan 29 universal PCR master mix (Applied Biosys-
tems), and 1 lL TaqMan microRNA assay probe contain-
ing PCR primers and TaqMan probes were added and run
in triplicate on an ABI Prism 7500 HT sequence detection
system (Applied Biosystems) at 95 C for 10 min followed
by 40 cycles at 95 C for 15 s and 60 C for 1 min.
Changes in miR-1 expression were normalized to
SNORD48 expression, and calculated with the 2-DDCt
method. Each test was performed in triplicate.
ELISA and Western blot assay
After 48 h of transfection, conditioned medium was
removed and analyzed by ELISA for detection of secreted
VEGF-A (human VEGF QuantiGlo ELISA kit, R&D
Systems, Minneapolis, MN, USA). In parallel, whole-cell
lysates were prepared with radioimmunoprecipitation assay
lysis buffer supplemented with protein enzyme inhibitors.
The protein concentration was determined by use of the
bicinchoninic acid assay. Equal amounts of protein (20 ug
per lane) were subjected to sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis and transferred to
poly(vinylidene difluoride) membranes. The membranes
were blocked with 5% fat-free milk in tris(hydrox-
ymethyl)aminomethane-buffered saline (TBS) (pH 7.5) for
1 h at room temperature, and then incubated with anti-
VEGF-A (ab9570, Abcam), anti-entothelin 1 (ab113697,
Abcam), anti-MET (sc-8307, Santa Cruz Biotechnol-
ogy), or anti-GAPDH (sc-47724, Santa Cruz Biotechnol-
ogy) antibodies overnight at 4 C. After incubation with
the appropriate horseradish peroxidase conjugated sec-
ondary antibody (Pierce) for 1 h at room temperature,
membranes were incubated with enhanced chemilumines-
cence reagent and visualized in a Syngene gel documen-
tation system.
Cell proliferation and migration assay
To assay cancer cells for proliferation, they were seeded at
a density of 3000 cells per well in a 96-well plate and
maintained in regular medium. Cell growth was monitored
by an IncuCyte live cell analysis system (Essen Instru-
ments, Ann Arbor, MI, USA), where the cell proliferation
was assessed by confluence measurements. Cell migration
was assessed with a wound-healing assay using the
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IncuCyte system. For this, cancer cells were seeded at a
density of 2 9 104 cells per well in 96-well plates. A
wound was made through confluent monolayer cells with a
pin block, and cells were washed with 19 phosphate-buf-
fered saline, and then cultured in regular medium. Pho-
tographs of cells were taken at 2-h intervals from two
separate regions per well with a 910 objective. Values
from two regions of each well were pooled and averaged
across all six replicates.
Endothelial cell culture and tube formation assays
Human microvascular endothelial cells (HMVECs) were
grown to confluence in 75-cm2 tissue culture flasks in
medium 131 supplemented with microvascular growth
supplement.
Supernatant from the BGC823 and AGS cells trans-
fected with GV268-miR-1 or a nonspecific GV268-ctrl
plasmid or the wild type was collected and centrifuged at
400g for 5 min. Purified supernatant then mixed with
medium 131 in a ratio of 2:1, and which served as condi-
tioned medium. HMVECs (3000 cells per well for prolif-
eration and 10,000 cells per well for migration) were
seeded in 96-well plates. After starvation, the supernatant
was replaced with conditioned medium [21]. The migration
of HMVECs was quantified by a wound healing assay with
use of the IncuCyte system as described earlier.
For tube formation assay, 50 lL of liquefied Matrigel
(BD Bioscience) was plated onto 96-well plates evenly and
incubated for 30 min at 37 C. A suspension of 5 9 104
HMVECs was loaded on the top of the Matrigel. The
conditioned medium was replaced after cell attachment.
Following incubation (24 h at 37 C, 5% CO2), pictures
from six replicates of each group were captured with a
Leica microscope, and the number of branches and nodes
were quantitated by Wimasis Image Analysis. All the
experiments were performed triplicate.
Reporter assay
The human VEGF-A and EDN1 30 untranslated region
(UTR; 1938 and 1126 bp respectively) containing the
putative binding sites of miR-1 (wild type) or an identical
sequence with mutations of the miR-1 seed sequence
(mutant) was amplified by PCR and then inserted into the
firefly luciferase reporter vector pEZX-MT06. For lucifer-
ase assay, COS-7 cells were seeded in a 96-well plate at a
density of 8000 cells per well. After overnight incubation,
about 70% confluent cells were transiently transfected with
150 lL Opti-MEM (Gibco, USA) containing 0.15 lL
Lipofectamine 3000 reagent (Invitrogen, USA) and 0.2 lL
P3000 reagent, 100 ng luciferase reporter plasmids, and
120 ng GV268-miR-1 or GV268-ctrl plasmid per well.
Cells were incubated for 6 h, and transfection medium was
replaced with the 500 lL fresh regular medium. Luciferase
activity was measured after incubation for 24 h with a
dual-luciferase reporter assay system (GeneCopoeia, USA)
by a microplate reader (Synergy HT, BioTek). Briefly, cells
were lysed with 20 lL lysis buffer per well. The culture
plate was incubated at -80 C overnight, 100 lL firefly
luciferase assay reagent was added to 20 lL lysate for the
first measurement, and 100 lL Renilla luciferase reagent
was added for the second measurement. The experiments
were performed independently in duplicate.
Statistical analysis
GraphPad Prism (version 6.01; GraphPad Software, La
Jolla, CA, USA) was used to calculate the statistical sig-
nificance of differences. Variance between three or more
experiments and/or wells was calculated by analysis of
variance and presented as the mean ± standard error of the
mean. Statistical analyses of duplicate data (paired samples
or unpaired samples) were determined by t tests or non-
parametric tests. The overall survival was calculated with
the Kaplan–Meier method and analyzed with the log-rank
test. All statistical tests were two-sided, and P\ 0.05 was
considered statistically significant.
Results
Expression of miR-1 in human GC cell lines
and primary GC samples
Previously we reported that miR-1 was the most signif-
icantly downregulated miRNAs in GC on the basis of
TCGA data [5]. To assess the miR-1 expression pattern
in Chinese patients with GC, we firstly performed qPCR
in GC cell lines and paired primary tissues from 90 GC
patients with or without metastasis at diagnosis. As
shown in Fig. 1a, miR-1 was obviously downregulated in
GC-derived cell lines compared with normal stomach-
derived cells (GES-1), and the expression level tended to
cFig. 1 MiR-1 expression in cultured gastric cancer (GC) cells and
primary GC tissues samples, and its correlation with prognosis of GC
patients a MiR-1 expression in GC cell lines compared with the
immortalized gastric cell line GES-1. b Quantitative PCR levels
showing reexpression of mature miR-1 in GC cell lines after 5-aza-20-
deoxycyridine (5-aza-dC) treatment. c Relative expression levels of
miR-1 in primary gastric tumors and adjacent nontumor tissues
(n = 90). The data represent 2-DDCt expression values. The P value
was calculated by a paired test. d Kaplan–Meier curves of overall
survival for all patients with miR-1-high versus miR-1-low GC tissue.
e Transfection efficiency of miR-1 in GC cells by qPCR .
Mean ± standard deviation of three independent experiments. WT
wild type, *P\ 0.05, **P\ 0.01, ***P\ 0.001, ****P\ 0.0001
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be decreased with poor differentiation. After treatment
with the demethylation agent 5-aza-dC, the level of miR-
1 expression was restored significantly in all the GC cell
lines examined compared with the wild-type cells, sug-
gesting that DNA hypermethylation may account for
miR-1 downregulation in GC cells (Fig. 1b). MiR-1 was
also frequently downregulated in primary tumors com-
pared with paired nontumor tissues (P\ 0.0001)
(Fig. 1c).
Relationship between miR-1 expression
and clinicopathological characteristics
We then analyzed the association of miR-1 expression
status with clinicopathological features in GC patients.
Recent reports tend to suggest that expression level
changes between tumor and paired nontumor samples
may be more correlated with cancer relapse and survival
than expression levels in tumor samples alone, Huang
et al. [22] reported that adjacent normal samples’ tran-
scriptional levels likely provided complementary infor-
mation on patient survival through systematic evaluation
of transcription profiles of tumor adjacent to normal
samples across multiple cancer cohorts using the TCGA
pancancer data. Thus fold changes of tumor to nontumor
miR-1 expression were adopted for evaluation—namely, a
patient with a ratio less than one third was defined as
having low expression, and a patient with a ratio greater
than or equal to one third was defined as having high
expression. As shown in Table 1, GC patients with low
miR-1 expression showed a higher potential to develop
vascular invasion, lymph node involvement, and distant
metastasis (respectively 55.6% vs 30.8%, P = 0.033;
44.8% vs 30.4%, P = 0.040; and 81.8% vs 44.3%,
P = 0.020). The proportion of patients with low miR-1
expression tended to increase with advanced TNM stages
(P = 0.143). Kaplan–Meier survival curves showed that
overall survival was worse in GC patients with low miR-1
expression compared with GC patients with high expres-
sion (P = 0.0027, Fig. 1d). Multivariate analysis was
then performed on the following factors known to impact
survival: tumor stage, tumor location, tumor size, vascular
invasion, age, sex, and miR-1 expression. N category and
M category demonstrated the most significant impact on
survival (P = 0.004 and P\ 0.0001). MiR-1 expression
did not retain statistical significance with regard to sur-
vival (P = 0.108, Table 2). In contrast, when we con-
sidered the interaction between miR-1 expression and
tumor stage, our multivariate analysis revealed the inter-
action between miR-1 expression and tumor stage was the
only independent factor associated with worse prognosis
of GC (P\ 0.001).
Overexpression of miR-1 suppressed proliferation
and migration of GC cells
SGC7901, BGC823, AGS, and HGC27 cells were trans-
fected with GV268-miR-1 plasmid, and the change in miR-
1 expression at different time points was assessed by qPCR
(Fig. 1e). Following transfection, cell proliferation and
wound healing assays were performed with the IncuCyte
system. The results showed that miR-1 significantly
inhibited both cell proliferation (Fig. 2a–d, P\ 0.05) and
cell mobility (Fig. 2e–h) in all the GC cells examined.
These results further indicate that miR-1 might act as a
tumor suppressor in GC.
MiR-1 inhibited VEGF-A, EDN1, and MET
expression in GC cells
MiRNA plays its role through regulating target gene
expression by translational repression or degradation of
mRNA in a sequence-specific manner. The TargetS-
canHuman (http://www.targetscan.org) algorithm predicted
that VEGF-A, EDN1, and MET were directly targeted by
miR-1. Furthermore, a protein array assay showed that
these three targets were downregulated in miR-1-overex-
pressed cells compared with control cells (data not shown).
Thus, we chose VEGF-A, EDN1, and MET for our further
analysis. To investigate the direct effect of miR-1 on these
predicted target genes in GC cells, the expression change
of these genes was analyzed by qPCR and Western blotting
at 48 h after miR-1 transfection. As shown in Fig. 3a and b,
ectopic expression of miR-1 significantly inhibited VEGF-
A, EDN1, and MET expression in GC cell lines at both the
transcription level and the protein level. Considering
VEGF-A is a paracrine growth factor, and the protein level
in culture medium derived from BGC823 and AGS cells
transfected with miR-1 or control was also assessed by
ELISA. As we expected, the result was similar to that from
Western blotting (Fig. 3c). We used antago-miR-1 to
knock down its expression in highly differentiated MKN28
tumor cells and immortalized GES-1 gastric epithelial
cells, both of which naturally express a relatively high level
of miR-1. We found that transfection of MKN28 and GES-
1 cells with antago-miR-1 caused a more than tenfold
decrease in miR-1 expression compared with the negative
control or the wild type (see Online Resource 3a in the
electronic supplementary material). We further tested the
changing level of VEGF-A, EDN1, and MET after miR-1
knockdown. The results revealed that inhibition of miR-1
expression significantly enhanced the expression of VEGF-
A, EDN1, and MET at both the mRNA level and the
protein level (see Online Resource 3b and c in the elec-
tronic supplementary material).
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MiR-1 interacts with a putative binding site
in the VEGF-A and EDN1 30 UTR
To determine whether miR-1 can inhibit VEGF-A and
EDN1 expression by targeting their binding sites in their
30 UTRs, the PCR product containing each intact target site
or mutant site of the miR-1 seed recognition sequence
(Fig. 4a) was inserted into the luciferase reporter vector.
COS-7 cells were transfected with these plasmids together
with the GV268-miR-1 plasmid or GV268-ctrl plasmid.
VEGF-A and EDN1 firefly luciferase activity normalized to
Renilla luciferase activity was significantly reduced in cells
co-transfected with miR-1 (P\ 0.05), but such reduction
was not found on negative control transfection (Fig. 4b).
On the other hand, the reporter vector lacking the miR-1
recognition site (mutant) fully rescued the miR-1 repres-
sion of both VEGF-A and EDN1 luciferase activity
(Fig. 4b), indicating that miR-1 directly and specifically
interacts with the target site in the VEGF-A and EDN1
30 UTRs.
MiR-1 suppressed HMVEC proliferation,
migration, and tube formation
Since VEGF-A and EDN1 have been implicated in the
angiogenesis and metastasis [23, 24], and the expression of
Table 1 Relationship between
miR-1 suppression and
clinicopathological features in
Chinese gastric cancer patients
MiR-1 suppression v2 Pa
Positive Negative
Sex 0.600 0.549
Male 30 (46.9%) 34 (53.1%)
Female 14 (53.8%) 12 (46.2%)
Age (years) 0.319 0.750
C60 23 (51.1%) 22 (48.9%)
\60 21 (47.7%) 23 (52.3%)
Tumor location 0.844 0.399
Cardia 11 (57.9%) 8 (42.1%)
Noncardia 30 (46.9%) 34 (53.1%)
Tumor size (cm) 1.845 0.065
B4 1 (14.3%) 6 (85.3%)
[4 40 (50.6%) 39 (49.4%)
Histological differentiation 1.685 0.092b
Moderate 0 (0.0%) 3 (100.0%)
Poor 43 (49.4%) 44 (50.6%)
Vascular invasion 2.128 0.033
Absent 8 (30.8%) 18 (69.2%)
Present 35 (55.6%) 28 (44.4%)
Depth of invasion 0.6265 0.531b
T1 2 (66.7%) 1 (33.3%)
T2–T4 42 (48.3%) 45 (51.7%)
Lymph node involvement 1.655 0.040
No 7 (30.4%) 16 (69.6%)
Yes 30 (44.8%) 37 (55.2%)
Distant metastasis 2.294 0.022
M0 35 (44.9%) 43 (55.1%)
M1 9 (81.8%) 2 (18.2%)
TNM stage 6.114 0.057c
I 0 (0.0%) 1 (100.0%)
II 2 (20.0%) 8 (80.0%)
III 31 (47.0%) 35 (53.0%)
IV 9 (81.8%) 2 (18.2%)
a v2 test
b Fisher–Kruskal–Wallis test
c Linear correaltion coefficient test
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both VEGF-A and EDN1 was inhibited by miR-1 in our
study, it is possible that miR-1 might participate in
angiogenesis. To prove this assumption, we next investi-
gated the effect of conditioned medium collected from
BGC823 and AGS cells transfected with GV268-miR-1 or
GV268-ctrl plasmid on endothelial cell proliferation,
wound healing, and tube formation. As expected,
HMVECs showed remarkable inhibition of cell growth,
migration, and tube formation when cultured in condi-
tioned medium derived from the miR-1-transfected cells
compared with control ones (P\ 0.05, Fig. 5).
Discussion
Previous findings obtained from miRNome analysis of GC
patients from TCGA revealed that miR-1 was the most
downregulated miRNA in GC (see Online Resource 1 in
the electronic supplementary material). In this study, qPCR
analysis revealed that loss of miR-1 expression was fre-
quently observed in primary gastric tumors compared with
adjacent normal tissues, which was consistent with the data
observed in breast, lung, colon, and hepatocellular carci-
noma [7–10]. Intriguingly, some studies suggested an
upregulation of plasma miR-1 in GC patients, including
those who developed resistance to chemoagents [13, 14],
by comparison with healthy individuals. However, there
are increasing reports that miRNAs may be exported via an
extracellular-vesicle-based active efflux mechanism,
resulting in circulating miRNAs [25, 26].
In this study, we also observed an association between
miR-1 expression and clinicopathological factors. Low
miR-1 expression was positively related to lymph node
involvement, vascular invasion, and distant metastasis.
Furthermore, downregulation of miR-1 was negatively
associated with 5-year survival rate. These results were
Table 2 Results of univariate
and multivariate Cox
proportional hazards regression
analysis for overall survival of
Chinese gastric cancer patients
Parameter Univariate Multivariate
5-year survival rate (%) (mean ± SE) P Relative riska P
Depth of invasion 0.284 0.707 (0.088–5.673) 0.696
T1 60.00 ± 0.00
T2–T4 31.44 ± 2.25
Lymph node involvement 3.215 (1.201–8.601) 0.004
No 48.74 ± 3.68 0.000
Yes 26.65 ± 2.35
Distant metastasis 0.002 3.592 (1.335–9.667) 0.000
M0 31.81 ± 2.60
M1 15.86 ± 2.62
MiR-1 expression 0.003 1.961 (0.458–2.019) 0.108
Low 36.63 ± 2.05
High 27.69 ± 2.14
Tumor size (cm) 0.119 1.525 (0.329–7.065) 0.378
B4 44.45 ± 8.99
[4 31.11 ± 2.29
Vascular invasion 0.042 1.178 (0.527–2.634) 0.149
Absent 42.03 ± 4.14
Present 29.21 ± 3.06
Tumor location 0.003 1.408 (0.762–2.604) 0.395
Low 36.63 ± 2.05
High 27.69 ± 2.14
Sex 0.213 1.222 (0.589–2.536) 0.590
Male 34.29 ± 2.61
Female 26.94 ± 4.20
Age (years) 0.040 2.042 (0.965–2.425) 0.082
B60 34.95 ± 3.24
[60 28.44 ± 3.00
SE standard error
a The 95% confidence interval is given in parentheses
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Fig. 2 Overexpression of miR-1 suppressed the proliferation and
migration capability of GC cells. a–d Cell growth curves. The y-axis
is a label-free measure of cell confluence used for the IncuCyte
ZOOM live cell imaging system to assess the cell growth. e–
h Wound-healing curves. Cell motility was monitored by the
IncuCyte ZOOM live cell imaging system. WT wild type
MicroRNA-1 acts as a tumor suppressor microRNA by inhibiting angiogenesis-related growth…
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Fig. 3 MiR-1 inhibited angiogenesis-related factors at both the
messenger RNA level and the protein level. a Quantitative reverse
transcription PCR assay. P values were determined by an unpaired
two-sided t test. b Western blotting. c Relative protein levels of
vascular endothelial growth factor A (VEGF-A) in supernatant of
gastric cancer cells transitorily transfected with pri-miR-1 plasmid
determined by ELISA. Cont. control, WT wild type, *P\ 0.05,
**P\ 0.01, ***P\ 0.001, ****P\ 0.0001
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consistent with the negative prognostic value of downreg-
ulated miR-1 expression in prostate cancer [27], colon
cancer [28], and breast cancer [29]. In our multivariate
analysis, low miR-1 expression alone exerted a marginal
effect on the prognosis of GCs. Intriguingly, the interaction
between miR-1 and stage was an independent factor for GC
prognosis in the multivariate model, indicating that a
strong association between miR-1 expression and tumor
stage plays a profound role in GC pathogenesis. Hence,
further investigations are warranted in a larger cohort.
Previously, methylation-mediated silencing of miR-1
was found in hepatocellular carcinoma [7], prostate cancer
[27], and colorectal cancer [30]. We treated GC cell lines
with a demethylating agent, 5-aza-dC, and assessed miR-1
expression by qPCR. Our data revealed a remarkable
upregulation of mature miR-1 expression in all the GC cell
lines examined, which is in accordance with previous
findings, indicating hypermethylation may partly con-
tribute to miR-1 suppression in GC.
Since miR-1 was downregulated in most of the GC cell
lines, our gain-of-function experiments demonstrated that
overexpression of miR-1 in GC cells attenuated the evil
character of GC cells, such as proliferation and invasive-
ness, significantly compared with control groups. To
identify the potential target of miR-1, we combined a
bioinformatics prediction (TargetScanHuman) and a pro-
tein array assay. We selected three candidates: VEGF-A,
EDN1, and MET. Western blot, qRT-PCR, and ELISA
confirmed that overexpression of miR-1 in four GC cell
lines significantly decreased VEGF-A, EDN1, and MET
expression. We also knocked down miR-1 in MKN28 and
GES-1 cells using antago-miR-1, and showed that inhibi-
tion of miR-1 expression significantly enhanced expression
of MET and VEGF-A at the mRNA level and the protein
level. These results were supported by the negative corre-
lation between miR-1 expression and mRNA expression of
MET and VEGF-A in our Chinese cohort (see online
resource 2a and b in the electronic supplementary material)
as well as the GC patients recruited in TCGA (see Online
Resource 2d and e in the electronic supplementary mate-
rial). EDN1 exerted a weak correlation with miR-1
expression (see Online Resource 2c and f in the electronic
supplementary material), however, the correlation failed to
reach statistical significance in both cohorts. It may be
explained by a more complicated molecular regulation in
tissue samples than in vitro cell experiments. Taken toge-
ther, our data imply a possible major role of miR-1 in
downregulating VEGF-A andMET rather than EDN1. MET
overexpression enhanced anchorage-independent growth,
tumorigenesis, and experimental metastasis in vivo [31].
Furthermore, MET kinase inhibitors abolished cancer
growth and reduced the tumor-associated angiogenesis in
experimental tumor [32]. We found miR-1 directly targeted
MET, which was supported by a recent report [33]. In
addition, we identified VEGF-A and EDN1 as two direct
targets of miR-1. These findings could partially explain
why overexpression of miR-1 could suppress the aggres-
siveness of GC.
VEGF-A, EDN1, and MET [34–36] are all major
angiogenic factors involved in development and mainte-
nance of blood vessels. We thus hypothesized that GC cells
may downregulate miR-1 expression to tilt the balance
toward stimulatory angiogenic factors to drive vascular
growth, resulting in the development of GC metastasis. In
this study, overexpression miR-1 in GC cells affected the
endothelial cell tubular formation activity in a co-culture
Fig. 4 MiR-1 inhibits the expression of VEGF-A and EDN1 30 un-
tranlated region (UTR)-integrated luciferase reporter genes. a The
target sites for miR-1 in the VEGF-A (NM_001025369.2), and EDN1
(NM_001955.4) 30 UTR were identified with the TargetScan
database. b Luciferase reporter assay using the vector encoding the
full-length 30 UTR of VEGF-A, and EDN1 30 UTR messenger RNA.
The Renilla luciferase values were used to normalize firefly luciferase
values. Cont. control, Mut mutant, Wt wild type, *P\ 0.05,
**P\ 0.01
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system study, implying that miR-1 may modulate gastric-
tumor-related angiogenesis by regulating VEGF-A and
EDN1. Recent studies have shown that EDN1 [37] and
VEGF-A [38] promoted tumor progression via an angio-
genesis-independent action of epithelial–mesenchymal
transition, which may provide a plausible explanation for
our observations that miR-1 inhibited the proliferation and
migration of GC. Hence, our results suggest that loss of
miR-1 expression was significantly correlated with metas-
tasis and poor prognosis in primary GC. Further study will
be warranted to confirm the antiangiogenetic biological
effect of miR-1 and to determine whether miR-1 is directly
involved in epithelial–mesenchymal transition in GC by
use of an animal model.
Collectively, low miR-1 expression is strongly associ-
ated with a poorer prognosis in patients with GC as well as
metastasis progression. These phenomena may be
explained by our observation that aberrant expression of
miR-1 direct targets, VEGF-A, EDN1, and MET, enhanced
GC progression and stimulated angiogenesis. Moreover,
targeting angiogenesis therapy is an effective component of
the treatment strategy for cancer patients, but its efficiency
is challenged by rapidly rising tumor resistance and limited
improvements in overall survival. Thus, we propose miR-1
as an additional target to improve antiangiogenesis therapy
in GC.
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